title: Reappraisal of OP-1206, a prostaglandin E1 derivative in combination with low-flow oxygen inhalation therapy in chronic lung disease.
abstract: For the purpose of alleviating pulmonary hypertension and maintaining cardiac output, which tended to be decreased to acute low-flow oxygen therapy in chronic lung diseases, we evaluated combined low-flow oxygen therapy and oral administration of OP-1206, a prostaglandin E1 derivative, in 7 patients with obstructive lung disease and 3 with restrictive one. Low flow oxygen inhalation (1 l/min. 30 minutes) increased PaO2 from 67.2 +/- 12.8 mmHg to 91.0 +/- 18.2 mmHg (p less than 0.001), PVO2 from 36.4 +/- 3.1 mmHg to 41.7 +/- 7.0 mmHg (p less than 0.01) and decreased cardiac index from 3.38 +/- 0.39 l/min/m2 to 3.07 +/- 0.32 l/min/m2 (p less than 0.01), RVSWI from 18.7 +/- 2.6 g.m/m2 to 6.1 +/- 2.0 g.m/m2 (p less than 0.01), transpulmonary driving pressure from 13.0 +/- 5.4 mmHg to 9.8 +/- 5.5 mmHg (p less than 0.01) and mean PA from 21.6 +/- 7.7 mmHg to 18.3 +/- 6.9 mmHg (p less than 0.05) with a trend of increase in COD and no change at oxygen delivery. OP-1206, on the contrary, decreased mPA from 21.6 +/- 7.7 to 18.2 +/- 5.6 mmHg (p less than 0.05), RVSWI from 8.7 +/- 2.6 g.m/m2 to 6.9 +/- 2.3 g.m/m2 (p less than 0.01) with trend of decrease in transpulmonary driving pressure, TPVR and PAR with no substantial changes in gasometric parameters. The decrease rates of PA by low-flow oxygen therapy and OP-1206 administration correlated significantly.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Third Department of Internal Medicine, Fukui Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ishizaki
authors.forename: I
authors.initials: I
authors.lastname: Yamamura
authors.forename: H
authors.initials: H
authors.lastname: Azuma
authors.forename: F
authors.initials: F
authors.lastname: Sasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Kishi
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Ameshima
authors.forename: S
authors.initials: S
authors.lastname: Miyabo
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002302:Cardiac Output / Q000187:drug effects; D003131:Combined Modality Therapy; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000503:physiopathology / Q000628:therapy*; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged; D010102:Oxygen Inhalation Therapy; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D014665:Vasodilator Agents; C025090:ONO 1206; D000527:Alprostadil